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ORIGINAL INVESTIGATION
Sitagliptin improved glucose 
assimilation in detriment of fatty-acid utilization 
in experimental type-II diabetes: role of GLP-1 
isoforms in Glut4 receptor trafficking
E. Ramírez1, B. Picatoste1, A. González‑Bris1, M. Oteo2, F. Cruz2, A. Caro‑Vadillo3, J. Egido1,5, J. Tuñón4, 
M. A. Morcillo2 and Ó. Lorenzo1,5* 
Abstract 
Background: The distribution of glucose and fatty‑acid transporters in the heart is crucial for energy consecution 
and myocardial function. In this sense, the glucagon‑like peptide‑1 (GLP‑1) enhancer, sitagliptin, improves glu‑
cose homeostasis but it could also trigger direct cardioprotective actions, including regulation of energy substrate 
utilization.
Methods: Type‑II diabetic GK (Goto‑Kakizaki), sitagliptin‑treated GK (10 mg/kg/day) and wistar rats 
(n = 10, each) underwent echocardiographic evaluation, and positron emission tomography scanning for 
 [18F]‑2‑fluoro‑2‑deoxy‑d‑glucose (18FDG). Hearts and plasma were isolated for biochemical approaches. Cultured 
cardiomyocytes were examined for receptor distribution after incretin stimulation in high fatty acid or high glucose 
media.
Results: Untreated GK rats exhibited hyperglycemia, hyperlipidemia, insulin resistance, and plasma GLP‑1 reduction. 
Moreover, GK myocardium decreased 18FDG assimilation and diastolic dysfunction. However, sitagliptin improved 
hyperglycemia, insulin resistance, and GLP‑1 levels, and additionally, enhanced 18FDG uptake and diastolic function. 
Sitagliptin also stimulated the sarcolemmal translocation of the glucose transporter‑4 (Glut4), in detriment of the fatty 
acyl translocase (FAT)/CD36. In fact, Glut4 mRNA expression and sarcolemmal translocation were also increased after 
GLP‑1 stimulation in high‑fatty acid incubated cardiomyocytes. PI3K/Akt and AMPKα were involved in this response. 
Intriguingly, the GLP‑1 degradation metabolite, GLP‑1(9‑36), showed similar effects.
Conclusions: Besides of its anti‑hyperglycemic effect, sitagliptin‑enhanced GLP‑1 may ameliorate diastolic dysfunc‑
tion in type‑II diabetes by shifting fatty acid to glucose utilization in the cardiomyocyte, and thus, improving cardiac 
efficiency and reducing lipolysis.
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Introduction
More than 300 million people worldwide currently suf-
fer from type-II diabetes mellitus (T2DM) [1]. Diabetic 
cardiomyopathy (DCM) is defined by functional and 
structural changes at the myocardium, independent of 
any vascular or cardiac disease [2]. However, DCM and 
dyslipidemia-associated vasculopathies or hypertension 
frequently coexist in T2DM subjects, and despite access 
to a variety of treatments, cardiovascular diseases are 
the main cause of death in this population [3]. Besides 
of fatty acids (FA), glucose is a crucial source of energy 
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in the heart, especially after injury. Damaged hearts shift 
energetic substrate toward highly efficient glucose in det-
riment of FA, but this metabolic flexibility is impaired 
under insulin resistance, leaving to FA as unique fuel pro-
vider. However, an oversupply of lipids can saturate mito-
chondria, producing toxic and oxidative metabolites, and 
cardiac dysfunction [4]. In this regard, cardiac function 
has been improved described in patients with heart fail-
ure after balancing lipid degradation toward glucose oxi-
dation [5]. Also, overexpression of glucose transporter-4 
(Glut4) stimulated glucose delivery, reduced FA utiliza-
tion, and enhanced cardiac performance in obese/T2DM 
mice [6]. In consonance, deletion of FA-translocase 
(FAT)/CD36 receptors prevented myocyte triacylglycerol 
accumulation, increased glucose utilization and amelio-
rated cardiac dysfunction in PPARα-overexpressed mice 
resembling T2DM [7]. Thus, regulation of main cellular 
receptors for glucose and/or FA could represent a prom-
ising therapeutic target for DCM.
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, 
has demonstrated insulin dependent and independent 
cardio-protective actions in DCM by increasing gluca-
gon-like peptide-1 (GLP-1), and following activation of, 
at least, its pancreatic and cardiac receptors (GLP-1R) 
[8, 9]. In pancreas, GLP-1R activation stimulated insulin 
secretion, whereas in the cardiovascular system, it pro-
moted anti-fibrotic/-hypertrophic/-apoptotic responses 
[10, 11]. However, the effects of sitagliptin on cardiac 
energetic substrate uptake, in particular, on Glut4 and 
FAT/CD36 distribution have not been elucidated. In 
addition, previous data suggest that the main degradation 
peptide of GLP-1, GLP-1(9-36), may also interact with 
GLP-1R or different receptors to induce cardio-salutary 
actions [10, 12]. Therefore, both GLP-1 and GLP-1(9-36) 
could trigger direct insulin-mimetic effects on cardio-
myocytes and enhance cardiac alterations associated to 
T2DM.
Materials and methods
Experimental model of T2DM
A polygenic non-obese non-hypertensive model of 
T2DM was used in this work. Goto-Kakizaki (GK) rats 
exhibit similar metabolic, hormonal and vascular disor-
ders that the human T2DM, offering a convenient model 
for the study of T2DM per se, without the confounding 
effects of obesity or hypertension. Male GK (Taconic, 
Denmark) were kept on artificial 12-h light–dark cycles 
(7 a.m.–7 p.m.) at 25 °C. Animals had free access to chow 
and water. Once T2DM became well-established (at the 
25th week), rats were daily treated (at 10 a.m.) with sitag-
liptin [Merck Sharp & Dohme (Spain), 10 mg/Kg/day] or 
vehicle by a gavage, as previously described [10]. Sex and 
aged-matched wistar rats were also examined (N =  10, 
each group). Body weight, diet consumption and sys-
tolic blood pressure (measured by tail-cuff method) were 
weekly monitored. After 20  weeks of sitagliptin-admin-
istration, plasma (collected from cava vein) and hearts 
were isolated (at 3–7  p.m.) under 1.5% isoflurane-O2 
anaesthesia. Plasma glucose, lipid profile, hepatic and 
renal parameters were enzymatically measured in the 
clinical department of the Hospital. Hearts were rinsed, 
dried, and weighted. After atria excision, left ventricles 
were frozen in liquid-N2 for biochemical assays. These 
investigations adhered to the Guide for the Care and 
Use of Laboratory Animals (NIH Publication No. 85–23, 
revised 1996), and the Ethics Committee of the IIS-Fun-
dación Jiménez Díaz Hospital granted approval for these 
experiments.
Glucose homeostasis and OGTT
One day before sacrifice, blood samples were collected 
(from tail vein) following overnight fasting (n = 7, each 
group). Then, rats received the corresponding treatment 
and plasma was immediately obtained, after which, glu-
cose solution (0.5 g/kg) was orally administrated. Fifteen 
and sixty minutes later, plasma was taken again. Glucose 
and insulin were measured by ELISA kits (Mercodia AB; 
Sweden). GLP-1 was also determined by modification 
of Orskov method [13]. Briefly, samples were isolated in 
glass tubes with DPP-4 inhibitors (Vacutainer P700, BD; 
USA)], mixed with 0.5  M EDTA, 10,000  UIC/ml apro-
tinin and absolute ethanol, and centrifuged. Supernatants 
were snap-frozen, lyophilized and dissolved in 0.2  M 
glycin-0.5% human serum albumin-500  U/ml aprotinin 
solution. One hundred microlitre were used for GLP-1 
quantification by ELISA (Epitope Diagnostic Inc.; USA). 
The homeostasis model assessment (HOMA) was used to 
assess insulin resistance (IR) from fasting plasma glucose 
and plasma insulin levels as it follows: 
Small‑animal PET imaging
Positron emission tomography (PET) was achieved in the 
animals at the end of the model in the Centro de Inves-
tigaciones Energéticas, Medioambientales y Tecnologicas 
(CIEMAT). All the animal experiments were approved by 
the Animal Ethical Committee of this institution. After 
1 week of acclimatization, wistar, GK and GK-sitagliptin 
rats (n = 3–6) were anesthetized with 1.5–2% isoflurane 
in 100% oxygen. Then,  [18F]-2-fluoro-2-deoxy-d-glucose 
(18FDG, 30–50  MBq) was injected via the tail vein. 
Dynamic 60-min images were acquired in list-mode 
using a small-animal PET scanner (Argus PET-CT, 
SEDECAL) and reconstructed using a 2D-OSEM 
(Ordered Subset Expectation Maximization) algorithm 
HOMA-IR = fasting plasma glucose (mM)
× fasting insulin (mU/ml)/22.5.
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(16 subsets and two iterations), with random and scat-
ter correction. The region of interest (ROI) templates as 
visualized on the late phase PET images were used for 
measuring 18FDG uptake of myocardium. Isocontour 
function using a threshold of 40% of maximal uptake was 
used to make template ROIs. 18FDG uptake was obtained 
from the ROIs between 20 and 40  min and quantified 
using a standardized uptake value (SUV). This was calcu-
lated according to the following equation:
Cardiac structure and function
Transthoracic echocardiography was performed under 
1.5% isoflurane-O2 anaesthesia in all rats before (not 
shown) and after the treatment. Both M-mode and two-
dimensional (2D) echocardiograms were obtained using 
a 12 MHz ultra-band sector transducer (En Visor-C-HD, 
Philips). Images were obtained from the left and right 
parasternal window in a supine decubitus position. The 
following parameters were measured and calculated from 
M-mode tracing: left ventricular (LV) end-diastolic diam-
eter (LVDD), LV end-systolic diameter (LVSD), ejection 
fraction (EF; by Teichholz method), deceleration time 
and the ratio of the early (E) to late (A) ventricular filling 
velocities. The wall thicknesses of four segments [ante-
rior, inter-ventricular-septum (IVS), lateral, and posterior 
(LVPW) walls] were evaluated on short axis 2D images. 
LV mass was estimated following formula [14]; 
Cultured cardiomyocytes
Mouse C2C12 myoblasts (ATCC, USA) were kindly 
given by Dr. Konhilas (University of Arizona, USA), and 
maintained in DMEM supplemented with 9% foetal calf 
serum, 5 mM d-glucose, 50 U/ml penicillin, and 50 μg/
ml streptomycin. Before confluency, the medium was 
replaced to differentiation medium containing DMEM 
and 2% horse serum. After 4 additional days, the differen-
tiated C2C12 cells fused into myotubes. Then, cells were 
switched to serum-free quiescent medium overnight 
before stimulation. The hyperlipidemic or hyperglyce-
mic conditions were mimicked by 6–12  h incubation 
with high concentrations of a common saturated free 
FA (FFA)  [Na+-palmitate (16:0), 0.12  mM], or glucose 
(d-glucose, 25 mM), respectively (Sigma). These concen-
trations were not lethal after 12 h incubation [15]. Palmi-
tate was previously conjugated with BSA in a 3:1 molar 
ratio as published earlier [15]. In control cells, BSA was 
added as described but in the absence of palmitate. Some 
cells were pre-treated with GLP-1 (1 nM) or GLP-1(9-36) 
SUV =
Activity concentration in VOI (Bq/cm3)
Injected activity (Bq)/Weight of the animal (g)
LV mass = 1.053×
[
(LVDD+ LVPW+ IVS)3 − LVDD3
]
.
(0.3  nM) (Sigma) 30  min before stimulation. Wortman-
nin (50 nM) was added 1 h before stimulation.
Particulate fractions and Western Blot (WB)
To quantify total cellular content of specific proteins 
(FABP3, PPARα, SPTLC2 and PDK4), a piece (~ 50 mg) 
of homogenized LV (Bullet Bender, Next Advance) was 
dissolved in ice-cold protein lysis buffer A (50 mM Tris–
HCl pH 7.5, 1 mM EDTA, 2% SDS + 1/250 mammalian 
protease inhibitors). To evaluate the glucose- and FA-
transporters distribution, a piece (~  50  mg) of homog-
enized LV was suspended in ice-cold lysis buffer B (2 mM 
EDTA, 2 mM phenyl-methyl-sulfonyl fluoride, and 1 µM 
pepstatin A in PBS). Cytosolic proteins were collected 
in supernatant after cold centrifugation at 50,000g for 
30  min. The pellet, with sarcolemmal proteins was sus-
pended in ice-cold lysis buffer B. In  vitro, 50  μg of cell 
extracts from cultured cardiomyocytes were homog-
enized in ice-cold buffer C containing 1  mM EDTA, 
250 mM sucrose, and 10 mM Tris, pH 7.5. The homoge-
nates were cold-centrifuged (5 min at 760g), and super-
natants were isolated and centrifuged (1 h at 31,000g) to 
pellet the sarcolemma enriched-fraction. Then, the sec-
ond supernatant was subjected to centrifugation (1 h at 
190,000g) to pellet the endosome enriched-fraction.
Equal amounts of all protein extracts were loaded and 
separated on polyacrylamide gels, transferred to mem-
branes (iBlot, Thermo Fisher), and probed with spe-
cific primary antibodies anti-FABP3, -GPAT1, -SPTLC2 
(Aviva System Biology), -PDK4, -PPARα (Sigma Aldrich), 
-Glut4, -Glut1, -FAT/CD36, -phospho-AKT(Ser473), 
-phospho-AMPKα1(Ser496) or -phospho-IRS1(Ser307) 
(Thermo Fisher). Anti-GAPDH or anti-pan-cadherin 
(Sigma) were used as loading control for cytosol or sar-
colemma, respectively. Then, secondary antibodies (GE 
Healthcare) were used for chemo-luminescence devel-
opment. A representative gel of the rats or at least three 
independent experiments with the semi-quantification 
scores (n-fold) are shown.
Quantitative‑PCR (QPCR)
Total RNA was extracted from homogenized ventricle 
(~  50  mg) or cultured cardiomyocytes by dissolving in 
Trizol reagent (Thermo Fisher). Equal amounts of RNA 
were reverse-transcripted to obtain the cDNA for mul-
tiplex QPCR, as previously described [15]. The gene 
expression assays were Glut4 (Mn00436615_m1), FAT/
CD36 (Rn00580728_m1), acyl-CoA dehydrogenase long 
chain (ACADl) (Rn00562121_m1), acyl-CoA dehydro-
genase medium chain (ACADm) (Rn00566390_m1) and 
CPT1b (Rn00682395_m1) Fam-fluorophores. The house-
keeping gene was eukaryotic ribosomic 18s Vic-fluoro-
phore (4310893E). Amplification conditions were: 2′ at 
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50 °C, 10′′ at 95 °C and 40 cycles of 15′′ at 95 °C and 1′ at 
60  °C. All samples were prepared in triplicate to obtain 
their threshold cycle (Ct). If deviation for each triplicate 
were higher than 0.3 cycles, Ct was not considered. The 
relative expression for each gene was achieved following 
the model R = 2−ΔΔCt. We show the average quantifica-
tion (-fold gene vs. 18s) of two QPCRs of all rats or three 
independent cultured cardiomyocytes assays.
Statistical analysis
Data are expressed as mean ±  standard deviation. Mul-
tiple comparisons were performed by non-parametric 
Kruskal–Wallis test followed by a Mann–Whitney test. 
Statistical significance was defined from p < 0.05.
Results
Sitagliptin attenuated hyperglycemia and insulin 
resistance in GK rats
Compared to aged-matched wistar, GK rats exhibited a 
weight loss and elevation of circulating levels of glucose 
and lipids [triglycerides (TG), cholesterol (Ch), non-HDL 
Ch, high-density lipoproteins (HDL), and FFA] (Fig. 1a). 
Interestingly, 20  weeks of sitagliptin administration 
(10  mg/Kg/day) significantly attenuated hyperglycemia 
(Fig. 1a), though only tended to improve hyperlipidemia. 
A glucose tolerance test was also achieved at the end of 
the model. In a fasting state, GK exhibited higher lev-
els of plasma glucose and insulin, and reduced released 
of GLP-1 (0  min; Fig.  1b), suggesting insulin resistance. 
After 15  min of oral glucose loading, GK rats did not 
respond by adequately increasing GLP-1 and insulin 
(Fig.  1b, middle and bottom), leading to uncontrolled 
glycemia (Fig.  1b, top). However, sitagliptin-treated 
GK reacted after 15  min-glucose overload by stimulat-
ing GLP-1 and insulin, and thus, decreasing glycaemia 
by 60  min. In addition, the HOMA-IR index, a reliable 
measure of insulin resistance in human and rat [16], 
was elevated in GK rats and returned after sitagliptin 
(Fig. 1a). Of note, plasma ions  (Na+,  Cl− and  K+), mark-
ers of severe renal (urea, blood urea nitrogen, creatinine 
and albumin) and liver (aspartyl and alanine aminotrans-
ferases) injury, and systolic blood pressure remained 
within the normal ranges in all groups (not shown).
Sitagliptin improved glucose uptake and diastolic 
dysfunction in the GK myocardium
Since sitagliptin attenuated hyperglycemia and insu-
lin resistance, we examined whether this action may 
affect glucose uptake by the myocardium. In fact, myo-
cardial 18FDG uptake was decreased by 27% in GK rats 
compared to control rats although the difference was 
not statistically  significant (SUV: 2.105  ±  0.521 vs. 
2.667 ±  0.232, p =  0.06) (Fig.  2a). However, sitagliptin-
treated rats exhibited a dramatic increase of the glucose 
assimilation in the myocardium (3.068 ± 0.811).
Next, a defect in glucose uptake in T2DM hearts could 
originate cardiac dysfunction [16]. Thus, by 2D-Echo-
Doppler we evaluated cardiac dimensions and function 
in GK rats (Fig. 2b). GK exhibited a significant increase 
of the LV posterior wall (LVPW) thickness, and a reduc-
tion of LV diastolic and systolic diameters (LVDD and 
LVSD, respectively). Accordingly, LV mass was elevated 
in GK myocardia. As expected [10], GK rats preserved 
the ejection fraction, but they prolonged the deceleration 
time and diminished the E/A ratio, suggesting diastolic 
dysfunction (Fig.  2b). Interestingly, sitagliptin attenu-
ated these hypertrophic parameters, and lessen diastolic 
dysfunction.
Sitagliptin stimulated Glut4 translocation in detriment 
of FAT/CD36 in GK hearts
The stimulation of myocardial glucose uptake induced by 
sitagliptin may be dependent on glucose transporter traf-
ficking. After stimulation, both Glut4 and Glut1 recep-
tors are synthetized in the cytosol and translocated from 
endosome stores to the sarcolemma for glucose assimi-
lation [17]. In wistar rats, we detected most of Glut4 
in sarcolemmal fractions (Fig.  3a, left). However, GK 
myocardia showed a reduction in sarcolemmal, but not 
cytosolic, Glut4 isoform (Fig.  3a, left), and also, down-
regulation of Glut4 transcripts (Fig.  3b). Sitagliptin did 
not change cytosolic or mRNA Glut4, but it did restore 
sarcolemmal levels of Glut4 (Fig. 3a, right) and phospho-
Akt473 and phospho-AMPK496 levels (Fig. 3c), which may 
explain the increased glucose uptake observed by PET 
after treatment. Phospho-Insulin receptor substrate-1 
(IRS-1307) was, however, unchanged in the myocardia 
(not shown). In addition, Glut1 was also localized in the 
cytosol and in a lesser extent in the sarcolemma of wistar, 
but these isoforms were not significantly modified either 
in GK or GK-treated rats (Fig. 3d).
Since glucose and FA metabolism could be tightly cou-
pled and inversely regulated [18], we next analysed the 
levels of the most relevant FA transporter in the myo-
cardium. FAT/CD36 also synthetizes in the cytosol and 
moves away from endosome vesicles to the sarcolemma 
for FA uptake [17]. In this model, we detected FAT/CD36 
mainly in cytosolic fractions of wistar rats, but it was par-
tially shifted to sarcolemmal location in GK (Fig. 3e, left). 
In parallel, FAT/CD36 mRNA (Fig. 3f ), but not its cyto-
solic isoform (Fig.  3e, left), was increased. Interestingly, 
sitagliptin attenuated sarcolemmal FAT/CD36 transloca-
tion (Fig. 3e, right), suggesting a potential counterbalance 
with stimulated Glut4 transporters.
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Fig. 1 Sitagliptin reduced hyperglycemia and glucose intolerance in GK rats. a Body weight and plasma parameters were evaluated in the experi‑
mental model. TG, triglycerides; Ch, cholesterol, LDL and HDL, low‑ and high‑density lipoproteins, respectively, and FFA, free FA. N = 10, each group. 
b Plasma glucose, insulin and GLP‑1 were measured in fasting rats before (0 min) and after (15–60 min) an oral glucose loading (G). *p < 0.05 and 
**p < 0.01 vs. wistar. †p < 0.05 and ††p < 0.01 vs. GK rats. §p < 0.05 vs. 15 min glucose‑overload or fasting state. N = 7, each group
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GLP‑1 isoforms improved Glut4 translocation 
in HF‑stimulated cardiomyocytes
The beneficial effects of sitagliptin on cardiac glucose 
assimilation may be derived from incretin-associated 
stimulation of insulin secretion and sensitivity, and/
or from incretin direct actions on cardiac cells [10, 11]. 
Thus, we stimulated C2C12 cardiomyocytes with GLP-1 
under high concentrations of glucose (HG) or FA (HF), 
and quantified Glut4 distribution in endosomes and sar-
colemma. Like in hearts, Glut4 was mainly located in sar-
colemma fraction. Intriguingly, after 12 h of HG (Fig. 4a) 
or HF (Fig. 4b), Glut4 reduced its sarcolemmal expression 
with no significant changes in endosome location. How-
ever, GLP-1 stimulation enriched both sarcolemmal and 
endosome isoforms under HF environment (Fig. 4b). Fur-
thermore, similar effects were shown by pre-treatment 
with the main GLP-1 metabolite of DPP-4 activity, GLP-
1(9-36) (Fig. 4b). In order to know whether PI3K pathway 
could be involved in these responses, we also pre-treated 
some cardiomyocytes with Wortmannin, a specific PI3K 
inhibitor. Interestingly, Wortmannin attenuated sar-
colemmal Glut4 expression induced by GLP-1 (Fig.  4c, 
left) and GLP-1(9-36) (not shown), under HF medium. 
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Fig. 2 Sitagliptin improved myocardial glucose uptake and mitigated myocardial dysfunction in GK rats. a Left, cardiac PET images (sagittal, coronal 
and axial slices) of  [18F]‑FDG metabolism in (A) wistar, (B) GK and (C) GK‑treated rats. Color scale bars represent the standardized uptake value (SUV) 
range in the myocardia. Right, quantification of SUV in the animal model. b The left‑ventricular posterior wall (LVPW) and inter‑ventricular septum 
(IVS) thicknesses, left‑ventricular diastolic and systolic diameters (LVDD and LVSD, respectively), the ejection fraction (EF), deceleration time, and the 
E/A ratio were measured in the rats. Representative Echo‑Doppler images for each group are also shown (top). *p < 0.05 and **p < 0.01 vs. wistar. 
†p < 0.05 and ††p < 0.01 vs. GK rats. N = 8, each group
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However, its endosome expression did not decrease sig-
nificantly (Fig. 4c, right).
Consequently, in order to explain the endosomal 
increase of Glut4 after GLP-1 and GLP-1(9-36) incre-
tins in HF milieu, we quantified Glut4 mRNA expression 
by QPCR in the cardiomyocytes. Glut4 transcripts were 
initially triggered by HF, but progressively decreased up 
to 12 h (Fig. 4d, left). Importantly, both GLP-1 and GLP-
1(9-36) recovered Glut4 mRNA levels after 12  h of HF 
incubation (Fig. 4d, right).
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Sitagliptin reduced FA utilization in GK myocardia
The enhanced glucose uptake and the increased bal-
ance of sarcolemmal Glut4 over FAT/CD36 in sit-
agliptin-treated rats may promote a decrease in FA 
utilization [17]. Due to the short half-life of radi-
olabelled FA tracers, we could only quantify the FA 
assimilation by indirect measurement of downstream 
mediators for FA-transport, -oxidation and -storage. 
Interestingly, the GK-induced over-expression of a 
key FA cytosolic carrier named FA-binding protein-3 
(FABP3), was significantly restored after sitagliptin 
(Fig.  5a). Also, the GK-associated increase of carnitine 
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palmitoyl transferase-1b (CPT1b) mRNA expression, a 
mitochondrion transporter for FA, was ameliorated by 
sitagliptin (Fig.  5b). Downstream, two central enzymes 
of FA oxidation (FAO), ACADl and ACADm, showed 
a similar response (Fig.  5b). Furthermore, a common 
transcription factor inducer of FAT/CD36, CPT1b, 
ACADl and ACADm expression, peroxisome prolifera-
tor-activated receptor-α (PPARα) [19], was also reduced 
after sitagliptin administration (Fig.  5c, left). However, 
lipid re-synthesis and ceramide formation may not be 
triggered in GK myocardia, and thus, not affected by sit-
agliptin. In this sense, glycerol-3-phosphate acyltrans-
ferase-1 (GPAT-1) and serine palmitoyltransferase-C2 
(STPLC2), the first rate-limiting enzymes of triacylglyc-
erol and ceramide biosynthesis, respectively, were not 
stimulated in GK rats and were unchanged after treat-
ment (Fig. 5c).
Finally, the expression of a crucial interconnecting 
enzyme between FA and glucose metabolic pathways 
was studied. Pyruvate dehydrogenase kinase-4 (PDK4), 
a PPARα-dependent inhibitory enzyme of the glycolytic 
pyruvate dehydrogenase complex [19], was triggered in 
GK myocardia but restored after sitagliptin administra-
tion (Fig.  5d). This data enforces the potential cardiac 
anti-lipolysis action of sitagliptin by restoring the balance 
toward glucose utilization in GK rats.
Discussion
According to the Framingham Heart Study, the risk of 
heart failure in diabetes is increased 2.4-fold in men and 
fivefold in women compared to non-diabetic subjects 
[20]. In this study, we observed that non-hypertensive 
non-obese T2DM (GK) rats exhibited hyperglycemia 
and hyperlipidemia, inefficient production of insulin and 
GLP-1, and also cardiac dysfunction. Importantly, this 
systemic insulin resistance may be mirrored at the myo-
cardium. By PET, GK decreased cardiac glucose assimila-
tion which was paralleled to a reduction in sarcolemmal 
content of Glut4 and Akt/AMPKα activation, while FAT/
CD36 was elevated. Similar data were observed in T1DM 
[21] and obese-T2DM [22–27] animals. These data sug-
gest that heart may suffer from insulin resistance in obe-
sity and T2DM, and FA could be preferred as energetic 
substrate in these conditions. In this regard, metabolic 
mediators of FA utilization may be upregulated. We 
observed that cytosolic and mitochondrial FA-transport-
ers (FABP3 and CPT1b), and FAO enzymes (ACADl and 
ACADm) were over-expressed in GK myocardia. Moreo-
ver, a related transcription factor such as PPARα, and a 
glycolytic inhibitor such as PDK4, were also stimulated. 
Thus, under glucose deficit and insulin resistance, most 
FA could be used for FAO and energy consecution in the 
heart. In this sense, we did not observe stimulation of 
GPAT-1 and SPTLC2 as rate-limiting enzymes of DAG 
and ceramide formation, respectively. However, exces-
sive FAO could lead to ROS accumulation and mitochon-
drial uncoupling, becoming a maladaptive response that 
rise lipotoxicity and reduce energy efficiency [18]. In fact, 
our GK rats revealed cardiac hypertrophy and diastolic 
dysfunction.
Unfortunately, there is not an efficient and specific 
treatment for DCM. Intensive glycemic goals have failed 
to prevent cardiac complications in long-term diabetic 
patients or have even increased cardiovascular mortal-
ity [28]. New therapeutic strategies capable of preserv-
ing heart function while contributing to the overall care 
of diabetes may be required. In this line, a correction of 
the metabolic imbalance has led to positive outcomes. A 
reduction of cardiac FAO and/or stimulation of glucose 
oxidation improved heart failure, ischaemic injury, and 
DCM in mice and patients [29, 30]. In this work, sitag-
liptin, a DPP-4 inhibitor that prevents GLP-1 degradation 
into GLP-1(9-36) and other metabolites, reduced hyper-
glycemia and insulin resistance, and increased GLP-1 
levels in fasting and non-fasting states, as previously 
described [8, 31]. More importantly, sitagliptin stimu-
lated cardiac glucose assimilation and enriched Glut4 
(but not Glut1) at sarcolemma locations, in detriment of 
FAT/CD36. Similarly, Vyas et  al. described that exena-
tide, an agonist of GLP-1R, increased total Glut4 whereas 
Glut1 was unchanged [32]. Although Glut1 could com-
pensate Glut4 lessening at least in hypertensive and 
hypertrophied hearts [33, 34], Glut1 is constitutively 
present on plasma membranes of multiple tissues includ-
ing myocardium [35]. In consequence, FA utilization 
might be also reduced after sitagliptin administration. 
Indeed, the expression of FABP3, CPT1b, and ACADl 
and ACADm, was diminished in GK-treated hearts. 
Also, PPARα and PDK4, were lessened. Thus, sitagliptin-
stabilized GLP-1 may improve glucose assimilation, and 
co-ordinately, decline excessive FA utilization and subse-
quent potential mitochondrial saturation and ineffective-
ness. By balancing metabolic and oxidative state, diabetic 
hearts could enhance their structure and performance 
[36]. In fact, GK-treated rats exhibited an improvement 
of cardiac hypertrophy and diastolic dysfunction. How-
ever, despite evidence from clinical studies have dem-
onstrated that sitagliptin could exert cardioprotection 
after specific heart injury (i.e., ischemia) [37], this inhibi-
tor could not reduced LV diastolic dysfunction and lipid 
profile in T2DM subjects [38]. Likely, both the presence 
of different DPP-4-targets than GLP-1 and the absence 
of GLP-1 degradative molecules [i.e., GLP-1(9-36), GLP-
1(28-36)] may affect cardiovascular pathophysiology in 
diabetes. In this sense, DPP4 could also act as a direct 
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Fig. 5 Sitagliptin reduced FA‑delivery and FAO mediators in GK rats. Protein expression of a FABP3, c PPARα, GPAT1, SPTLC2 and d PDK4 in wistar, GK 
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mediator of endothelial dysfunction, via PAR2 activation 
and prostanoids release [39].
Interestingly, GLP-1 actions can be partially driven in 
an insulin-independent and myocardial specific fashion 
[12]. GLP-1R has been found in extra-pancreatic tissue 
like heart, and thus, GLP-1 could increase myocardial 
glucose uptake independently of its ability to enhance 
insulin secretion [40]. Also, sitagliptin stimulated myo-
cardial 18FDG uptake in non-diabetic patients with 
dilated cardiomyopathy, without altering glucose homeo-
stasis [30]. We now demonstrate that GLP-1 ameliorated 
HF-associated insulin resistance in cultured cardiomyo-
cytes by up-regulation of both sarcolemmal and endo-
some Glut4 isoforms. GLP-1 also overexpressed Glut4 
mRNA expression after 12  h HF-incubation. However, 
GLP-1 did not alleviate Glut4 levels after HG incuba-
tion, possibly because HG can also bind Glut4 and might 
induce a negative feed-back regulation by itself [41] or by 
its deviation products (i.e., hexosamines) [42]. Thus, we 
hypothesize that GLP-1 may directly promote both Glut4 
translocation and mRNA expression after HF in the myo-
cardium, as previously seen in insulin resistant muscle 
and liver, via PI3K/Akt and/or AMPK activation [43, 44]. 
In fact, sitagliptin-treated hearts exhibited a moderate 
increase of phospho-Akt476 and phospho-AMPKα496 in 
parallel to Glut4 translocation. Accordingly, the enrich-
ment of sarcolemmal Glut4 induced by GLP-1 in HF-
incubated cardiomyocytes, was attenuated by a specific 
PI3K inhibitor. This data confirms the participation of the 
axes Akt/PI3K and AMPKα, likely activated by GLP-1R 
stimulation [42, 44].
However, some GLP-1 activities may be also ascribed 
to GLP-1(9-36). This non-insulinotropic peptide is pre-
sent in the circulation at higher levels than GLP-1 [45], 
though it shows 100-fold lower affinity for pancreatic 
GLP-1R [46, 47]. Remarkably, GLP-1(9-36) exhibited 
similar effects to GLP-1 as anti-fibrotic/apoptotic fac-
tor on cardiomyocytes [10], and reduced cardiac injury 
in ischemia/reperfusion models by GLP-1R dependent 
or independent mechanisms [12]. Also, GLP-1(9-36) 
induced vasodilatation through nitric oxide formation 
[12], and protected against oxidation in cardiac and 
vascular cells [48–50]. Here we show that GLP-1(9-36) 
improved cardiomyocyte Glut4 expression and sarcolem-
mal translocation after HF, in a similar way than GLP-1. 
GLP-1(9-36) may also activate GLP-1R and downstream 
Akt/PI3K and AMPKα mediators. Thus, the sequen-
tial modification of GLP-1 by DPP-4 from an insulino-
tropic to an insulinomimetic hormone [i.e., GLP-1(9-36)] 
could be also beneficial for cardiovascular protection 
[46]. These data also supports the insulin-independent 
actions of incretins and support the major outcomes of 
GLP-1R agonists over DPP-4 inhibitors [51]. In addition, 
GLP-1(9-36) may yield to a variety of N-terminal cleav-
age products, such as GLP-1(28-36), with demonstrated 
anti-oxidative proprieties [47].
Limitation of the study
The evaluation of FA assimilation by PET at the myocar-
dia could have added important information to our quan-
tification of FA-transporters and enzymes. However, due 
to the extremely short half-life (~  20  min) of a labelled 
FFA (i.e.,  [11C]-FFA) and the distance to the centre of syn-
thesis, we could not achieve this approach. Also, despite 
we confirmed a weight-neutral effect of sitagliptin, it also 
reduced the food intake by 13% (p  <  0.05), which may 
have contributed to the results.
Conclusions
Since cardiac dysfunction is dramatically increasing in 
T2DM patients, new insulinomimetic-based interven-
tions with cardioprotective proprieties are required. In 
this regard, sitagliptin improved hyperglycemia and insu-
lin resistance in GK rats, and also, it enhanced cardiac 
glucose assimilation in detriment of excessive FA utili-
zation and likely lipotoxicity. The sitagliptin-stabilized 
incretin, GLP-1, could inversely regulate sarcolemmal 
location of Glut4 and FAT/CD36 in cardiomyocytes via 
PI3K/Akt and AMPKα, but similar actions could be also 
triggered by GLP-1(9-36) metabolite. Therefore, these 
effects may occur independent of insulin regulation, 
opening the therapeutic utility to other cardiomyopathies 
different than DCM.
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